Maduramicin

Drug Profile

Maduramicin

Alternative Names: CL 259971; CL 273703; Maduramicin ammonium

Latest Information Update: 23 Aug 2006

Price : $50

At a glance

  • Originator Wyeth
  • Class Acetic acids; Antifungals; Ionophores; Lactones
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cryptosporidiosis

Most Recent Events

  • 23 Aug 2006 Discontinued - Preclinical for Cryptosporidiosis in USA (unspecified route)
  • 03 May 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
  • 22 Jul 1997 Preclinical development for Cryptosporidiosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top